human growth hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
The findings of the study were overall regarded as not supporting the hypothesis that (R)-MDMA would produce equivalent therapeutic effects as (S)-MDMA or MDMA whilst reducing safety concerns. However, more clinical studies were called for to assess the revised estimated equivalent doses of MDMA, (R)-MDMA, and (S)-MDMA.
== Interactions == Products containing multivalent cations, such as aluminium- or magnesium-containing antacids, and products containing calcium, iron, or zinc invariably result in marked reduction of oral absorption of fluoroquinolones. Other drugs that interact with fluoroquinolones include sucralfate, probenecid, cimetidine, theophylline, warfarin, antiviral agents, phenytoin, cyclosporine, rifampin, pyrazinamide, and cycloserine. Administration of quinolone antibiotics to a benzodiazepine-dependent individual can precipitate acute benzodiazepine withdrawal symptoms due to quinolones displacing benzodiazepines from their binding sites. Fluoroquinolones have varying specificity for cytochrome P450, so may have interactions with drugs cleared by those enzymes; the order from most P450-inhibitory to least, is enoxacin > ciprofloxacin > norfloxacin > ofloxacin, levofloxacin, trovafloxacin, gatifloxacin, moxifloxacin.
Immunomodulators Inhibitors of protein kinases Opioids Analgesics Treatment of benign prostatic hyperplasia Antiadrenergic drugs Hormonal treatments Diuretics Antiretroviral therapy Antihistamines Antidepressants *"For most of the drugs that are likely to affect spermatogenesis and/or sperm parameters, the levels of scientific evidence are still insufficient (with the exception of Sirolimus, Sulfasalazine, exogenous testosterone, Finasteride and Cyproterone acetate, for which the levels of evidence are higher). In some cases, data in men do not even exist, and the toxicity of a drug for the male reproductive organs is determined solely on the basis of animal models." **"For a certain number of pharmaceutical molecules that are likely to affect the sexual function of men being treated, the actual imputability of the drug is often difficult to pinpoint owing to the effect of the illness itself on sexuality (cardiovascular disease and erectile dysfunction; depressive illness and loss of desire, etc.)" Furthermore, hyperthyroidism, an excess of thyroid hormones, has been associated with reduced semen volume, reduced sperm density, motility, and morphology. Studies in humans show that an excess of circulating thyroid hormones during thyrotoxicosis results in asthenozoospermia, oligozoospermia, and teratozoospermia. These abnormalities frequently associate with semen alterations like reduced semen volume.
Sources: en.wikipedia.org
It was a formidable fighting force consisting of 1,487 tanks, 1,384 infantry fighting vehicles, 568 artillery pieces, 132 MLRS, 8 missile launchers, and 242 attack helicopters. It had a total troop strength of 146,321 troops. Its primary full strength fighting formations were the 1st Armored Division (United States), the 3rd Armored Division (United States) and the 1st Infantry Division (United States). The 2nd Armored Division (Forward) was assigned to the 1st Infantry Division as its third maneuver brigade. Its Task Force 1-41 Infantry would be the spearhead of VII Corps. In addition, the corps had the 2nd Cavalry Regiment (United States) to act as a scouting and screening force, and two further heavy divisions, the 1st Cavalry Division (United States) and the United Kingdom's 1st Armoured Division, as well as the U.S. 11th Aviation Group. VII Corps fought a number of large battles against Iraqi forces, with some of historic scope and size. Three of the battles at Norfolk, Medina Ridge, and 73 Easting are considered among the largest tank battles in history. By the end of combat operations on 28 February 1991, U.S. VII Corps had driven 260 kilometres (160 mi), captured 22,000 Iraqi soldiers, and destroyed 1,350 Iraqi tanks, 1,224 armored personnel carriers, 285 artillery pieces, 105 air defense systems, and 1,229 trucks.
=== Sexual role reversal === It is common among Lepidoptera for females to use pheromones to attract males for mating. In T. ni, both males and females produce pheromones capable of attracting the opposite sex. This has been cited as an example of sexual role reversal.
The Islamic Republic of Iran was identified as interfering with the 2024 presidential election through front companies connected to the Islamic Revolutionary Guard Corps and hacking attempts against the Trump, Biden, and Harris campaigns starting as early as May 2024. The Iranian regime launched propaganda and disinformation campaigns through fake news websites and accounts on social media to tip the election against former president Trump. The New York Times stated the efforts were an attempt at "sowing internal discord and discrediting the democratic system in the United States more broadly in the eyes of the world."
Sources: en.wikipedia.org
The role of electricity in the nervous systems of animals was first observed in dissected frogs by Luigi Galvani, who studied it from 1791 to 1797. Galvani's results inspired Alessandro Volta to develop the Voltaic pile—the earliest-known electric battery—with which he studied animal electricity (such as electric eels) and the physiological responses to applied direct-current voltages. In the 19th century scientists studied the propagation of electrical signals in whole nerves (i.e., bundles of neurons) and demonstrated that nervous tissue was made up of cells, instead of an interconnected network of tubes (a reticulum). Carlo Matteucci followed up Galvani's studies and demonstrated that injured nerves and muscles in frogs could produce direct current. Matteucci's work inspired the German physiologist, Emil du Bois-Reymond, who discovered in 1843 that stimulating these muscle and nerve preparations produced a notable diminution in their resting currents, making him the first researcher to identify the electrical nature of the action potential. The conduction velocity of action potentials was then measured in 1850 by du Bois-Reymond's friend, Hermann von Helmholtz. Progress in electrophysiology stagnated thereafter due to the limitations of chemical theory and experimental practice. To establish that nervous tissue is made up of discrete cells, the Spanish physician Santiago Ramón y Cajal and his students used a stain developed by Camillo Golgi to reveal the myriad shapes of neurons, which they rendered painstakingly.
== Mali == Adame Ba Konaré – historian, writer, and former First Lady of Mali (wife of president Alpha Oumar Konaré) Afel Bocoum - singer Bah Mamadou Cheick Oumar Dabo Demba Barry, footballer Lassana Diallo Sékou Amadou (1775–1846) – founder and First Shaykh of the Maasina Empire in 1817. Baréma Bocoum – politician and diplomat. former foreign minister of Mali and former member of French National Assembly. Mali. Boubacar Alpha Bah - Malian economist, former minister of Territorial Administration and Decentralization. Cissé Mariam Kaïdama Sidibé - former prime minister of Mali (1948–2021) Kaïta Kayentao Diallo - jurist, first female president of the Supreme court Of Mali. Mahmoud Dicko– Sunni imam, Mali Yoro Diakité- former prime minister, Mali. Amadou Hampâté Bâ – writer and ethnologist, Mali. Abdoulaye Sékou Sow – former prime minister, Mali. Moussa Léo Sidibé - former Minister of Agriculture, Husbandry and Fishery. Madina Ly-Tall – historian and diplomat, Mali. Mandé Sidibé - former prime minister. Malick Sidibé - Malian photographer. Oumar Tatam Ly – former prime minister, Mali. Oumou Sangaré - Malian singer. Inna Modja - singer Aïssata Cissé - First Female journalist, Mali Adama Ouane – former Minister, former Administrator of Organisation internationale de la Francophonie (OIF), Mali Alpha Oumar Konaré, former president of the republic (Fulani mother), Mali Diallo Lalla Sy - Former Minister of Employment and the Civil Service, Mali. N'Diaye Ramatoulaye Diallo - Former Minister of Handicrafts, Tourism and Culture, Mali.
== Significance in carryover assessment == The pathological range of measurement could be of several order to reference interval(e.g., Sex hormone, Tumor marker, Troponin...etc.). A small portion of carryover could lead to erroneous results.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.